News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
25 women students to receive internship, training, and mentorship in Life Sciences segment
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
